[Skip to Content]
[Skip to Content Landing]
Views 235
Citations 0
Comment & Response
June 15, 2020

Comparing the Roles of Omalizumab and Ultraviolet Therapy in Treating Severe Pediatric Atopic Dermatitis

Author Affiliations
  • 1Korea University College of Medicine, Seoul, Korea
JAMA Pediatr. Published online June 15, 2020. doi:10.1001/jamapediatrics.2020.0960

To the Editor In their study, Chan et al1 report the effectiveness of omalizumab in treating severe pediatric atopic dermatitis, with significant clinical benefit. While these encouraging results suggest that omalizumab may be a viable treatment option for this patient group, the Editorial2 on this study succinctly raised the issue of cost-effectiveness because the cost of omalizumab administration could amount to greater than $100 000 per year. Thus, there needs to be a strong rationale for using omalizumab in favor of other treatment options.